Heidi Anne Duerr, MPH

Drawing parallels to diabetes and hypertension, Adam Friedman, MD, invokes the dangerous side effect of doing nothing in reframing treatment strategies.

Adam Friedman, MD, maps the AD comorbidity spectrum, from T2-driven diseases to sleep-related indirect consequences, and discusses clinical implications.

David Oberlin, MD, shares tips for integrating AAD insights and lessons into the clinic to improve patient care.

Daniel C. Butler, MD, discusses the underrepresentation of older adults in dermatology trials and what a 3-system framework for itch means for clinical practice

Liza O'Dowd, MD, discusses the drug's long road to FDA approval and what its oral delivery means for patients with plaque psoriasis.

With so many new options in dermatology, personalized medicine may be replacing guideline-driven care.

Jeff Yu, MD, discusses important issues in screening and addressing pediatric contact dermatitis at the AAD Annual Meeting.

At AAD 2026, Maria-Angeliki Gkini, MD, PhD, shared guidance on diagnosing and managing topical steroid withdrawal syndrome.

Liza O'Dowd, MD, shared insights on the latest data on icotrokinra at the AAD Annual Meeting.

During the late-breaking research session at the 2026 AAD Annual Meeting 2026, Mary Spellman, MD, shared successful news about intratumoral PH762 for cutaneous carcinomas.

Daniel C. Butler, MD, discusses adherence challenges, medication risks, and practical strategies to optimize dermatologic care in older adults.

Missed the late-breaking sessions? Review our quick guide of all the need-to-know data from AAD 2026.

Levy reflected on the importance of mentorship, collaboration, and the evolving landscape of pediatric dermatology at the Society for Pediatric Dermatology Pre-AAD Meeting.

Omar Noor, MD, FAAD, discusses strategies to improve psoriasis care for patients facing adherence challenges related to lifestyle or cognitive barriers.

Douglas DiRuggiero, DMSc, MHS, PA-C, emphasized that relying solely on body surface area underestimates psoriasis burden, particularly for patients with disease in high-impact or special areas.

Innovative acne treatments emerge, including sponge-derived therapies and microbiome strategies, promising a brighter future for patients.

The FDA’s decision was based on litifilimab’s phase 2 skin disease activity data.

Julio Gonzalez Paoli, MD, shares tips for early lupus diagnosis at the Elevate-Derm Fall Conference.

Baldwin discusses the latest advancements in acne and rosacea treatments, including innovative therapies and promising clinical trials.

Douglas DiRuggiero receives the prestigious Stead Silver Ford Honorary Award, celebrating his dedication and impact in dermatology and medical education.

A poster presented at Elevate-Derm found dupilumab significantly enhanced growth and reduces corticosteroid use in children with severe atopic dermatitis.

Explore cutting-edge insights from DERM 2025, focusing on innovative treatments and emerging research in dermatology for improved patient care.

Dermatology has the opportunity of directing and leading AI use in the field, according to David Cotter, MD, PhD.

Tips for leveraging the right topical to improve patient outcomes from Linda Stein Gold, MD.

Adam Friedman, MD, shares tips for recognizing and addressing tinea at the DERM 2025 conference.

DERM 2025 featured tips and tricks for a thorough pruritus diagnosis and treatment strategy from Adam Friedman, MD.

The DERM 2025 midway recap includes tips for atopic dermatitis, chronic hand eczema, and pruritus.

Rheumatologist Karim Ladak, MD, shared diagnostic and treatment tips for cutaneous lupus at DERM 2025.

At the DERM 2025 conference, Scott Boswell, MD, shares tips for combining therapies.